A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
NCT06854653
Recruiting
This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL). PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles, then 21 day cycle thereafter. Subjects will be treated or followed up, if subjects discontinue treatment, for up to 18 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Yale Cancer Center, New Haven, Connecticut +9 locations
Conditions: CTCL
Register for Updates
Scrambler Therapy With Duloxetine-based Usual Care vs Duloxetine-based Usual Care for Chemotherapy Induced Peripheral Neuropathy
NCT06914557
Recruiting
The Investigators hypothesize that Scrambler therapy with duloxetine compared to duloxetine-based usual care will result in greater improvement in CIPN as measured by the BPI-Short Form. In addition, the Investigators will further assess pain using the EORTC CIPN-20 and determine whether Scrambler therapy will result in improved levels of function as measured with the PDQ, and decreased need for opioid medications. Our primary objective Investigate whether Scrambler therapy with duloxetine is s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: CIPN - Chemotherapy-Induced Peripheral Neuropathy, Pain
Register for Updates
Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer
NCT03400215
Recruiting
The role of fat in breast cancer development and growth has been studied extensively using body mass index, a measure of whole body fatness, and dietary fat intake in a number of epidemiological studies. However, there is a paucity of studies, on an individual level, to assess the role of breast fat itself in breast cancer due to lack of a non-invasive and fast measurement method. Since breast fibroglandular cells are surrounded by breast fat cells, the characteristics of breast fat may have a s... Read More
Gender:
FEMALE
Ages:
Between 25 years and 99 years
Trial Updated:
03/31/2025
Locations: NYU Langone Health, New York, New York
Conditions: Breast Cancer
Register for Updates
Cardiovascular and Neurovascular Regulation in GWI
NCT04586049
Recruiting
Brain blood flow regulation and autonomic dysfunction will be measured in Veterans with and without Gulf War Illness who served in the Gulf War between 1990 and 1992.
Gender:
ALL
Ages:
Between 45 years and 68 years
Trial Updated:
03/31/2025
Locations: University of Wisconsin-Madison, Madison, Wisconsin
Conditions: Brain Blood Flow, Neurovascular Control
Register for Updates
Randomized Trial of Sedative Choice for Intubation
NCT05277896
Recruiting
Among critically ill adults undergoing emergency tracheal intubation, one in five experience hypotension, cardiac arrest, or death. The sedatives used to rapidly induce anesthesia for emergency tracheal intubation have been hypothesized to effect cardiovascular complications and patient outcomes, but the optimal sedative medication for intubation of critically ill adults remains unknown. Ketamine and etomidate are the two most commonly used sedatives during intubation of critically ill adults. D... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: UAB Hospital, Birmingham, Alabama +5 locations
Conditions: Acute Respiratory Failure
Register for Updates
Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector
NCT05432310
Recruiting
The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from mobilized peripheral blood (mPB) of ADA-deficient SCID infants and children following human ADA gene transfer by the EFS-ADA lentiviral vector. The level of gene transfer in blood cells and immune function will be measured as endpoints.
Gender:
ALL
Ages:
1 month and above
Trial Updated:
03/31/2025
Locations: University of California, Los Angeles (UCLA), Los Angeles, California
Conditions: Adenosine Deaminase Severe Combined Immune Deficiency
Register for Updates
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT05552157
Recruiting
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: University of Alabama in Birmingham, Birmingham, Alabama +34 locations
Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Register for Updates
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176
Recruiting
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: University of California San Diego UCSD - Moores Cancer Center, La Jolla, California +56 locations
Conditions: Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
Register for Updates
Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures
NCT05851898
Recruiting
The goal of this pilot study is to learn about the feasibility about prescribing anti-depressants at discharge in patients aged 50 years and older with a lower extremity fragility fracture. The main questions it aims to answer are: * What are the obstacles to enrolling patients and prescribing anti-depressants among older adults? * Is it possible to start prescribing SNRI medication upon discharge? * What is the prevalence of depressive symptoms amongst patients with different types of injuries... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/31/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Depression in Old Age, Fragility Fracture
Register for Updates
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
NCT06001385
Recruiting
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it aims to answer are: * Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? * Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Mayo Clinic Arizona, Phoenix, Arizona +27 locations
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
Register for Updates
WE Project: 2.0 Grassroots Wellness Coaching (Phase 2)
NCT06172582
Recruiting
African American adults that live in economically disadvantaged areas are at an increased risk for obesity and cardiometabolic disease. The treatment program being tested in this research study aims to address these factors and increase outcomes for the study population. The purpose of this research study is to find out about the feasibility and acceptability of using house chats (HC) as a model for a weight loss program in a real-world, community-based setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Obesity
Register for Updates
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
NCT06298565
Recruiting
This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: SFM Clinical Research, LLC, Boca Raton, Florida +5 locations
Conditions: Myasthenia Gravis
Register for Updates